What we fund.

Alliance for Cancer Gene Therapy is helping to advance groundbreaking new therapies by funding the most promising cancer research being conducted by the boldest scientists at leading academic institutions, at innovative biotechnology companies and through unique collaborations with other key innovators.

What We Fund

With success in overcoming blood cancers established, our current funding priorities focus on new curative strategies for the most difficult-to-treat solid tumor cancers – glioblastoma, a brain cancer, and pancreatic cancer. Every study, every clinical trial, every success and even every failure strengthens the research community’s understanding of the immune system’s complexities and the biological building blocks that make cancer such a formidable foe.

Search below to learn more about Alliance for Cancer Gene Therapy-funded researchers and their work to cure cancer.

  

Filter research studies by:

Cancer immunotherapy is revolutionizing the treatment of many cancers. This revolution is being led by drugs that enhance the immune system’s T cell’s ability to kill cancer cells. This includes drugs such as Keytruda, an antibody…

Learn More

Brian Brown, PhD
Icahn School of Medicine at Mount Sinai

Major types of immunotherapy include checkpoint blockade, adoptive cell transfer, recombinant cytokines, and cancer vaccines. However, only a fraction of patients show sustained clinical responses.   These challenges demand new types of immunotherapies that are more potent…

Learn More

Sidi Chen, PhD
Yale University School of Medicine

Pancreatic cancer is a major public health problem with approximately 57,600 new cases in 2020. Five-year survival is less than 9% for all stages, with surgical resection the only potentially curative therapy. Nonetheless, a clear majority…

Learn More

Michael T. Lotze, MD
University of Pittsburgh School of Medicine

Many children, who are diagnosed with bone or muscle tumors (sarcomas), which have spread to more than one site in their body, cannot be cured. Thus, there is an urgent need to develop new therapies.   We…

Learn More

Stephen Gottschalk, MD
St. Jude Children’s Research Hospital

The immune system has many mechanisms to fight cancer, one of which is T cells. A common reason for failure of the immune system to eliminate tumors is that it does not recognize and kill “self”…

Learn More

Joseph Fraietta, PhD
University of Pennsylvania

Dendritic cells are potent antigen presenting cells capable of stimulating tumor immunity. Despite their promise as vectors for cancer vaccines, limited clinical efficacy has been observed to date. We have identified a fundamental metabolic pathway that…

Learn More

Brent Hanks, MD, PhD
Duke University Medical Center

Few procedures are available for physicians to rapidly and reliably harness immune responses to fight cancer. For example, bioinformatics tools can predict cancer proteins that T cells could react with, but vaccines developed from them commonly…

Learn More

Matthias Stephan, MD, PhD
Fred Hutchinson Cancer Research Center

Significant strides have been made in the treatment of solid tumors using viruses designed to attack and kill tumors (Oncolytic Viruses: OV) following direct injection into a detectable tumor mass. Tumor cell killing releases tumor-related proteins…

Learn More

Joseph Glorioso, PhD
University of Pittsburgh School of Medicine

Malignant brain tumors carry a dismal prognosis despite surgery, chemotherapy, and radiation, hence new therapeutic approaches are needed. New strategies are being investigated using modified viruses (termed “vectors”) to infect cancer cells and deliver genes that…

Learn More

Noriyuki Kasahara, MD, PhD
University of California

Ovarian cancer is the most lethal gynecologic cancer. However, women with evidence of immune cells in their ovarian cancer, specifically T cells, have an improved overall survival. This suggests that T cells control ovarian cancer growth.  …

Learn More

Daniel J. Powell, PhD
University of Pennsylvania